Related references
Note: Only part of the references are listed.An Infectious cDNA Clone of SARS-CoV-2
Xuping Xie et al.
CELL HOST & MICROBE (2020)
Immunology of COVID-19: Current State of the Science
Nicolas Vabret et al.
IMMUNITY (2020)
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan et al.
NATURE (2020)
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Ugur Sahin et al.
NATURE (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Philip J. M. Brouwer et al.
SCIENCE (2020)
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
Antonio E. Muruato et al.
NATURE COMMUNICATIONS (2020)
The Novel Coronavirus: A Bird's Eye View
Parham Habibzadeh et al.
INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2020)
RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial
Fatma Doener et al.
VACCINE (2019)
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques
Norbert Pardi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Robert A Feldman et al.
VACCINE (2019)
Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening
Alexandra G. Orlandini von Niessen et al.
MOLECULAR THERAPY (2019)
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
Norbert Pardi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
Norbert Pardi et al.
NATURE COMMUNICATIONS (2018)
New Vaccine Technologies to Combat Outbreak Situations
Susanne Rauch et al.
FRONTIERS IN IMMUNOLOGY (2018)
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Norbert Pardi et al.
NATURE (2017)
Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
Oi-Wing Ng et al.
VACCINE (2016)
A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
Wanbo Tai et al.
VIROLOGY (2016)
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
Norbert Pardi et al.
JOURNAL OF CONTROLLED RELEASE (2015)
mRNA-based therapeutics - developing a new class of drugs
Ugur Sahin et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies
Eric Destexhe et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2013)
Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
David N. Taylor et al.
VACCINE (2012)
Response definition criteria for ELISPOT assays revisited
Z. Moodie et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Selective CD4+ T cell help for antibody responses to a large viral pathogen:: Deterministic linkage of specificities
Alessandro Sette et al.
IMMUNITY (2008)
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Katalin Kariko et al.
MOLECULAR THERAPY (2008)
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
Silke Holtkamp et al.
BLOOD (2006)
Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia
Elisabeth Kamphuis et al.
BLOOD (2006)
Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials
Zoe Moodie et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2006)
The interferon gamma gene polymorphism+874 A/T is associated with severe acute respiratory syndrome
Wai Po Chong et al.
BMC INFECTIOUS DISEASES (2006)
Effect of influenza vaccine on markers of inflammation and lipid profile
MY Tsai et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2005)
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)
B Sainz et al.
VIROLOGY (2004)